test tubes in a row

Pipeline

Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

Pipeline
~90
compounds, devices or indications in development individually or under collaboration or license agreement
Close-up of a scientist wearing safety goggles and purple gloves inspecting a clear petri dish
investment
$13.8
b
R&D investment in 2025
Commitment
~60
programs are in mid and late-stage development
Development
6
programs granted a designation by at least one major regulatory authority to expedite delivery or review in 2025

Pipeline

Updated May 11, 2026

Sort By 
Focus Area
Molecule/Asset Phase
Molecule/Asset Type
Device Asset Phase
Device Asset Type
ABBV-8736
Biologic Immunology Pharmaceutical TREM1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease (CD)
N ∕ A
N ∕ A phase2
phase2
Tavapadon
Small Molecule D1 ∕ D5 Partial Agonist Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
N ∕ A
N ∕ A submitted
submitted
TrenibotE
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Glabellar Lines
N ∕ A
N ∕ A submitted
submitted
ABBV-1758
Biologic Pyroglutamate (3pE) Aβ Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase1
phase1
ABBV-525
Small Molecule Pharmaceutical MALT1 Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-722
Immunology Small Molecule Pharmaceutical LPAR1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Idiopathic Pulmonary Fibrosis
N ∕ A
N ∕ A phase1
phase1
Systemic Sclerosis
N ∕ A
N ∕ A phase1
phase1
ABBV-142
Biologic Immunology Pharmaceutical LPAR1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Idiopathic Pulmonary Fibrosis
N ∕ A
N ∕ A phase1
phase1
ABBV-324
Biologic Pharmaceutical Oncology N ∕ A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-295
Long-Acting Amylin Analog Large Molecule Pharmaceutical Other Specialties
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Obesity
N ∕ A
N ∕ A phase1
phase1
ABBV-711
Small Molecule Pharmaceutical Oncology N ∕ A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-901
Biologic Pharmaceutical Oncology N ∕ A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ovarian Cancer
N ∕ A
N ∕ A phase1
phase1
Etentamig (ABBV-383)
CD3, BCMA Biologic Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Multiple Myeloma (MM)
N ∕ A
N ∕ A phase3
phase3
Immunoglobulin Light Chain (AL) Amyloidosis
N ∕ A
N ∕ A phase2
phase2
Temab-A (ABBV-400)
Biologic c-Met Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Colorectal Cancer
N ∕ A
N ∕ A phase3
phase3
Solid Tumors
N ∕ A
N ∕ A phase2
phase2
Gastroesophageal adenocarcinoma
N ∕ A
N ∕ A phase2
phase2
Non-Small Cell Lung Cancer
N ∕ A
N ∕ A phase2
phase2
IMGN151
Biologic FR-alpha Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Gynecologic Cancers
N ∕ A
N ∕ A phase2
phase2
Surzetoclax (ABBV-453)
BCL-2 Small Molecule Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Multiple Myeloma
N ∕ A
N ∕ A phase1
phase1
ABBV-2002
Biologic Pharmaceutical Neuroscience PAR-2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Migraine
phase2
phase2
ABBV-243
Integrin β7 (α4β7 and αEβ7) Biologic Immunology Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Inflammatory Bowel Disease (IBD)
N ∕ A
N ∕ A phase1
phase1
ABBV-547
Biologic Immunology IL-23 Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Psoriasis (PsO)
N ∕ A
N ∕ A phase1
phase1
Icalcaprant (ABBV-1354)
Small Molecule Pharmaceutical Neuroscience KOR antagonist
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Bipolar Depression
N ∕ A
N ∕ A phase2
phase2
Major Depressive Disorder (MDD)
N ∕ A
N ∕ A phase2
phase2
ABBV-1042
Small Molecule Pharmaceutical Neuroscience M4 Receptor
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Bipolar Mania
phase1
phase1
ABBV-319
Biologic Immunology Pharmaceutical CD19
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Sjogren's disease
N ∕ A
N ∕ A phase1
phase1
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase1
phase1
EMRELIS
Biologic c-Met Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Non-Small Cell Lung Cancer
US
US approved
approved
EPKINLY
Biologic Pharmaceutical Oncology CD3, CD20
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Diffuse Large B-cell Lymphoma
US , EU
US , EU approved
approved
Relapsed ∕ Refractory Follicular Lymphoma
N ∕ A
N ∕ A approved
approved
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
N ∕ A
N ∕ A phase2
phase2
First Line Follicular Lymphoma
N ∕ A
N ∕ A phase3
phase3
First Line Diffuse Large B-cell Lymphoma
N ∕ A
N ∕ A phase3
phase3
B-cell Non-Hodgkin lymphoma
N ∕ A
N ∕ A phase2
phase2
Richter's Syndrome
N ∕ A
N ∕ A phase2
phase2
ABBV-466 (SKYRIZI + ABBV-382)
Biologic Immunology IL-23 + anti-a4b7 mAb Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
N ∕ A
N ∕ A phase2
phase2
ABBV-181 (budigalimab)
Biologic Pharmaceutical Oncology PD1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid and Hematologic Tumors
N ∕ A
N ∕ A phase2
phase2
ABBV-701
Biologic Immunology TL1A Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Inflammatory Bowel Disease
N ∕ A
N ∕ A phase1
phase1
ABBV-932
Small Molecule Pharmaceutical DRD2 ∕ DRD3 Modulator Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Bipolar Depression
N ∕ A
N ∕ A phase2
phase2
Generalized Anxiety Disorder
N ∕ A
N ∕ A phase2
phase2
ABBV-9832 (Lutikizumab + Ravagalimab)
Biologic Immunology IL-1a ∕ 1b + CD40 antagonist Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Rheumatoid Arthritis (RA)
N ∕ A
N ∕ A phase2
phase2
ABBV-6628
C5 Biologic Pharmaceutical Eye Care
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Geographic Atrophy
N ∕ A
N ∕ A phase1
phase1
ABBV-619
Biologic Immunology Pharmaceutical CD19
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Autoimmune diseases
N ∕ A
N ∕ A phase1
phase1
Livmoniplimab (ABBV-151)
Biologic GARP-TGF-β1 Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hepatocellular Carcinoma
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase2
phase2
Non-Small Cell Lung Cancer
N ∕ A
N ∕ A phase2
phase2
Bretisilocin
Small Molecule Pharmaceutical Neuroscience Serotonin 5-HT2A receptor
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Major Depressive Disorder
N ∕ A
N ∕ A phase2
phase2
AGN-193408
Device N ∕ A Eye Care PGF2 alpha receptor
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Open Angle Glaucoma
N ∕ A
N ∕ A phase2
phase2
Ocular Hypertension
N ∕ A
N ∕ A phase2
phase2
Armour Thyroid
Biologic Pharmaceutical T3T4 Other Specialties
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hypothyroidism
N ∕ A
N ∕ A phase3
phase3
Surabgene Lomparvovec (ABBV-RGX-314)
Gene Therapy Pharmaceutical Eye Care VEGF
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
wet AMD (subretinal)
N ∕ A
N ∕ A phase3
phase3
wet AMD (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
Diabetic Retinopathy (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
UBRELVY
CGRP receptor Small Molecule Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Menstrual Migraine
N ∕ A
N ∕ A phase3
phase3
ABBV-2001
BCMA, CD38, CD3 Biologic Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Multiple Myeloma
N ∕ A
N ∕ A phase1
phase1
Pivekimab Sunirine (PVEK)
CD123 Biologic Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
BPDCN
N ∕ A
N ∕ A submitted
submitted
Acute Myeloid Leukemia
N ∕ A
N ∕ A phase2
phase2
ABBV-969
Biologic Pharmaceutical Oncology PSMA,STEAP1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
mCRPC
N ∕ A
N ∕ A phase1
phase1
ABBV-514
Biologic Pharmaceutical Oncology CCR8
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ELAHERE
Biologic FR-alpha Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platinum-Resistant Ovarian Cancer
N ∕ A
N ∕ A approved
approved
Platinum-Sensitive Ovarian Cancer
N ∕ A
N ∕ A phase3
phase3
QULIPTA
CGRP receptor Small Molecule Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Acute Migraine
OUS
OUS submitted
submitted
Menstrual Migraine
OUS
OUS phase3
phase3
Emraclidine
M4 PAM Small Molecule Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Schizophrenia
N ∕ A
N ∕ A phase2
phase2
Psychosis
N ∕ A
N ∕ A phase1
phase1
RINVOQ
Immunology Small Molecule JAK1 Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alopecia Areata
US , EU
US , EU submitted
submitted
Ankylosing Spondylitis
US , EU
US , EU approved
approved
Atopic Dermatitis
US , EU
US , EU approved
approved
Axial SpA
US , EU
US , EU approved
approved
Crohn's Disease
US , EU
US , EU approved
approved
Giant Cell Arteritis
US , EU
US , EU approved
approved
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase3
phase3
Psoriatic Arthritis
US , EU
US , EU approved
approved
Rheumatoid Arthritis
US , EU
US , EU approved
approved
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase3
phase3
Takayasu Arteritis
JA
JA phase3
phase3
Ulcerative Colitis
US , EU
US , EU approved
approved
Vitiligo
US , EU
US , EU submitted
submitted
BOTOX
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platysma Prominence
US
US approved
approved
Masseter Prominence
CN N ∕ A
CN approved
N ∕ A phase3
approved
phase3
Forehead Lines
CN
CN approved
approved
ABBV-166 (SKYRIZI + Lutikizumab)
Biologic Immunology Pharmaceutical IL-23 + IL-1a ∕ 1b
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Psoriatic Arthritis
N ∕ A
N ∕ A phase2
phase2
ABBV-848
Immunology Small Molecule Pharmaceutical IRAK4
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Rheumatoid Arthritis (RA)
N ∕ A
N ∕ A phase1
phase1
ABBV-706
Biologic Pharmaceutical Oncology SEZ6
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
First Line Small Cell Lung Cancer
N ∕ A
N ∕ A phase2
phase2
Relapsed ∕ Refractory Small Cell Lung Cancer
phase3
phase3
Neuroendocrine Neoplasms
N ∕ A
N ∕ A phase1
phase1
ABBV-1480
Biologic PD-1, VEGF Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Lutikizumab
Biologic Immunology Pharmaceutical IL-1a ∕ 1b
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase3
phase3
GemibotulinumtoxinA
SNAP-25 Biologic Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ventral Hernia Repair (VHR)
phase2
phase2
Tropoelastin
Facial Aesthetics Device Skin Deformities Aesthetics
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Atrophic Scars
N A
N A confirmation
confirmation
Next Generation Collagen Filler
N ∕ A Device Facial Contouring Aesthetics
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Facial Volume
N A
N A confirmation
confirmation
JUVEDERM VOLUMA XC
N ∕ A Device Aesthetics Age-Related Volume Loss
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Temple Augmentation
US
US approved
approved
JUVEDERM VOLITE XC
N ∕ A Device Skin Deformities Aesthetics
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Fine Line Reduction
US , EU , JA
US , EU , JA approved
approved
Neck Line Reduction
N A
N A confirmation
confirmation
HArmonyCa
N ∕ A Device Skin Deformities Aesthetics
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Mid-Face Volume
N A EU
N A confirmation
EU approved
confirmation
approved
JUVEDERM VOLBELLA XC
N ∕ A Device Aesthetics Infraorbital Hollowing
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Infraorbital Hollowing
US
US approved
approved
No Results Found Change your filter or search criteria.
No results found
Change your search criteria.
No results found
Change your search criteria.
Popular pages
No results found
Change your search criteria.
External links
No results found
Change your search criteria.

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Copyright © 2026 AbbVie Inc. North Chicago, Illinois, U.S.A.

No results found
Change your search criteria.